Role of PET/CT in Peritoneal Deposits Assessment

NCT06137417•Aya Khaled Mahmoud

Summary

• Suspected patients known to have a primary malignant tumour, patients with metastasis of unknown primary and had incidental peritoneal lesions and will do PET/CT for assessment of peritoneal deposits

Detailed Description

Suspected patients known to have a primary malignant tumour, patients with metastasis of unknown primary and had incidental peritoneal lesions and will do PET/CT for assessment of peritoneal deposits. we will find its diagnostic role.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•• Suspected patients known to have a primary malignant tumour, patients with metastasis of unknown primary and had incidental peritoneal lesions.

Exclusion Criteria

•• Patients unable to sit calm without movement during imaging.
•* Severely ill patients.
•* Patients unable to sleep in a fixed position for 20 minutes.
•* Pregnancy

Key Dates

Start Date

January 1, 2024

Primary Completion Date

January 1, 2026

Completion Date

March 15, 2026

Last Updated

November 18, 2023

Enrollment

ESTIMATED participants

Conditions

Peritoneal Metastases

Interventions

PET/CT

DEVICE

Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis

NCT06519591

Gastric Cancer Stage IVPeritoneal Metastases

View study

RECRUITING

Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics

NCT05722275

Gastric CancerPeritoneal Metastases

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 18, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Role of PET/CT in Peritoneal Deposits Assessment

Inclusion Criteria

Exclusion Criteria

Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis

Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics

Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies

A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10

Concomitant Intraperitoneal and Systemic Chemotherapy in Patients With Extensive Peritoneal Carcinomatosis of Gastric Origin

Systemic Antitumor Treatment with or Without Pressurized Intraperitoneal Aerosol Chemotherapy for Colon Peritoneal Metastases (PIPOX02)